RDY DR REDDYS LABORATORIES LTD
Price Chart
Executive Summary
Dr. Reddy's launched its generic Semaglutide Injection in Canada on May 15, 2026, following Health Canada approval on April 28, 2026. The company is the first to receive approval for a generic semaglutide in Canada, which is also the first G7 country to authorize the product. This expands Dr. Reddy's GLP-1 portfolio and demonstrates its ability to rapidly commercialize complex peptides.
Actionable Insight
This is a positive product launch catalyst for Dr. Reddy's, establishing first-mover advantage in the Canadian generic semaglutide market. Monitor for subsequent launches in other G7 markets and any revenue guidance updates in upcoming quarterly filings. The GLP-1 franchise build-out supports long-term growth narrative.
Key Facts
- Dr. Reddy's launched generic Semaglutide Injection in Canada on May 15, 2026.
- Health Canada Notice of Compliance (NOC) received on April 28, 2026.
- Dr. Reddy's is the first company to receive Health Canada approval for generic Semaglutide Injection.
- Canada is the first G7 country to grant market authorization for generic Semaglutide Injection.
- Product is indicated for once-weekly treatment of type 2 diabetes in adults.
- Available in 2 mg/pen and 4 mg/pen strengths (1.34 mg/ml concentration).
- Follows recent launch in India under brand name Obeda.
- CEO Erez Israeli highlighted GLP-1 therapies as a key focus area with active expansion across global markets.
Financial Impact
No specific revenue or financial figures disclosed in the filing. The launch expands addressable market in a high-growth GLP-1 category, but near-term financial contribution is unquantifiable from this filing alone.
Risk Factors
- Competitive response from Novo Nordisk or other generic entrants could erode market share and pricing.
- Regulatory or supply chain challenges in scaling production for additional markets.
- Semaglutide is indicated only for type 2 diabetes in Canada; obesity indication not covered by this launch.
- Historical performance on RDY reports shows negative average alpha at T+20, suggesting the stock may not fully price in positive news near-term.
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000334 |
| Document: 0001575872-26-000334-index.html | 0001575872-26-000334 |
| Document: 0001575872-26-000334.txt | 0001575872-26-000334 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
4d ago
|
6-K
| $13.45 awaiting T+1 | awaiting T+1 | — | $13.30 (−1.08%) |
|
Jun 5, 2026
9d ago
|
6-K
| $13.29 awaiting T+1 | awaiting T+1 | — | $13.30 (+0.11%) |
|
Jun 3, 2026
11d ago
|
6-K
| $13.02 $13.24 | ▲ +1.69% | ▲ +1.29% | $13.30 (+2.15%) |
|
Jun 1, 2026
13d ago
|
6-K
| $13.26 $13.03 | ▼ −1.73% | ▼ −1.88% | $13.30 (+0.30%) |
|
Jun 1, 2026
13d ago
|
6-K
| $13.26 $13.03 | ▼ −1.73% | ▼ −1.88% | $13.30 (+0.30%) |
|
May 29, 2026
16d ago
|
20-F
| $13.26 $13.03 | ▼ −1.73% | ▼ −1.88% | $13.30 (+0.30%) |
|
May 28, 2026
17d ago
|
6-K
| $13.52 $13.63 | ▲ +0.81% | ▲ +0.57% | $13.30 (−1.63%) |
|
May 28, 2026
17d ago
|
6-K
| $13.52 $13.63 | ▲ +0.81% | ▲ +0.57% | $13.30 (−1.63%) |
|
May 18, 2026
27d ago
|
6-K
| $13.60 $13.45 | ▼ −1.10% | ▼ −0.45% | $13.30 (−2.21%) |
|
May 18, 2026
27d ago
|
6-K
| $13.60 $13.45 | ▼ −1.10% | ▼ −0.45% | $13.30 (−2.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access